🏛️ Verified NIH Record • Updated 2026-08-18

Remibrutinib Open Label Roll-over Post-trial Access Protocol (NCT07456891)

An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Remibrutinib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Remibrutinib.

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.

Who can join: Review the eligibility criteria below.

Location: Novartis Investigative Site — Sofia

Age range: 18 Years to 100 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

  • Novartis Investigative Site — Sofia,
  • Novartis Investigative Site — Sofia,
  • Novartis Investigative Site — Varna,
  • Novartis Investigative Site — Hamilton, Ontario
  • Novartis Investigative Site — London, Ontario
  • Novartis Investigative Site — Québec, Quebec
  • Novartis Investigative Site — Verdun, Quebec
  • Novartis Investigative Site — Brno,
  • Novartis Investigative Site — Plzen Bolevec,
  • Novartis Investigative Site — Prague,
  • Novartis Investigative Site — Prague,
  • Novartis Investigative Site — Bordeaux,
  • Novartis Investigative Site — Brest,
  • Novartis Investigative Site — Montpellier,
  • Novartis Investigative Site — Paris,
  • Novartis Investigative Site — Rouen,
  • Novartis Investigative Site — Krosno, Krosno
  • Novartis Investigative Site — Poznan, Poland
  • Novartis Investigative Site — Gdansk,
  • Novartis Investigative Site — Gdansk,
  • Novartis Investigative Site — Poznan,
  • Novartis Investigative Site — Daegu, Dalseo gu
  • Novartis Investigative Site — Hwaseong-si, Gyeonggi-do
  • Novartis Investigative Site — Suwon, Gyeonggi-do
  • Novartis Investigative Site — Dongjak Gu, Seoul

📞 Contact the Study Coordinator

Phone: +41613241111

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Indication of the Parent Protocol clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗